Your browser is no longer supported. Please, upgrade your browser.
Settings
PLX Protalix BioTherapeutics, Inc. daily Stock Chart
PLX [NYSE]
Protalix BioTherapeutics, Inc.
Index- P/E- EPS (ttm)-0.35 Insider Own6.23% Shs Outstand148.38M Perf Week-0.35%
Market Cap67.27M Forward P/E- EPS next Y-0.06 Insider Trans0.00% Shs Float144.79M Perf Month13.89%
Income- PEG- EPS next Q-0.05 Inst Own9.62% Short Float2.11% Perf Quarter11.95%
Sales9.69M P/S6.94 EPS this Y52.50% Inst Trans- Short Ratio5.35 Perf Half Y-5.74%
Book/sh-0.44 P/B- EPS next Y79.30% ROA- Target Price3.30 Perf Year-30.24%
Cash/sh- P/C- EPS next 5Y25.00% ROE- 52W Range0.27 - 0.83 Perf YTD45.79%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-45.37% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low67.93% ATR0.05
Employees190 Current Ratio- Sales Q/Q-91.20% Oper. Margin- RSI (14)52.14 Volatility7.52% 11.88%
OptionableYes Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.53 Prev Close0.45
ShortableYes LT Debt/Eq- EarningsMar 05 BMO Payout- Avg Volume572.73K Price0.45
Recom- SMA20-0.87% SMA5010.77% SMA200-3.65% Volume304,009 Change0.76%
Apr-17-17Reiterated Rodman & Renshaw Buy $4 → $5
Apr-04-16Initiated Rodman & Renshaw Buy $3.50
Apr-23-15Upgrade Jefferies Hold → Buy $2 → $2.60
Nov-12-14Reiterated R. F. Lafferty Buy $8 → $5
Jan-24-14Initiated R. F. Lafferty Buy $8
May-02-12Reiterated Oppenheimer Outperform $9 → $11
May-02-12Downgrade Canaccord Genuity Buy → Hold $8 → $8
Apr-30-12Downgrade Auriga Buy → Hold $8 → $8
Oct-13-11Initiated Morgan Joseph Hold
Mar-17-11Downgrade WBB Securities Strong Buy → Buy $10
Nov-09-10Reiterated Oppenheimer Outperform $10 → $12
Oct-14-10Reiterated UBS Buy $9 → $10.75
Dec-02-09Reiterated Hapoalim Outperform $10 → $12
Sep-22-09Initiated Canaccord Adams Buy
Sep-02-09Initiated Hapoalim Outperform $10
Dec-01-08Reiterated Oppenheimer Outperform $6 → $4
Mar-11-08Initiated UBS Buy $6
Nov-20-07Initiated CIBC Wrld Mkts Sector Outperform $7
Feb-07-19 08:08AM  The Daily Biotech Pulse: Galapagos-Evotec Forge Fibrosis Partnership, Sanofi Earnings, Alector To Debut Benzinga -7.07%
Feb-05-19 07:00AM  Protalix BioTherapeutics Presents Preliminary Data from the BRIGHT Study of pegunigalsidase alfa for the Treatment of Fabry Disease at the 15th Annual WORLDSymposium 2019 GlobeNewswire -11.16%
Feb-03-19 10:09AM  The Week Ahead In Biotech: Conferences, Clinical Trials, Earnings And IPOs Benzinga
Jan-29-19 08:15AM  New Research: Key Drivers of Growth for Voya Financial, Conduent, Milacron, Altair Engineering, Genesis Healthcare, and Protalix BioTherapeutics Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire
Jan-28-19 07:00AM  Protalix BioTherapeutics to Present Preliminary Data from the BRIGHT Study of pegunigalsidase alfa for the Treatment of Fabry Disease at the 15th Annual WORLDSymposium 2019 GlobeNewswire
Jan-26-19 09:37AM  Does The Protalix BioTherapeutics, Inc. (NYSEMKT:PLX) Share Price Tend To Follow The Market? Simply Wall St.
Jan-18-19 09:10AM  Implied Volatility Surging for Protalix (PLX) Stock Options Zacks
Dec-18-18 01:46AM  Moving Average Crossover Alert: Protalix BioTherapeutics Zacks
Dec-17-18 07:00AM  Protalix BioTherapeutics Announces the Completion of Enrollment in the Phase III BRIDGE Clinical Trial of pegunigalsidase alfa for the Treatment of Fabry Disease GlobeNewswire -5.37%
Nov-07-18 11:25AM  Protalix (PLX) Reports Q3 Loss, Lags Revenue Estimates Zacks
10:21AM  Protalix: 3Q Earnings Snapshot Associated Press
07:00AM  Protalix BioTherapeutics Reports 2018 Third Quarter Results and Provides Corporate Update GlobeNewswire
Oct-31-18 10:32AM  Will Protalix (PLX) Report Negative Earnings Next Week? What You Should Know Zacks
Oct-29-18 07:00AM  Protalix BioTherapeutics to Hold Third Quarter 2018 Financial Results and Corporate Update Conference Call on November 7, 2018 GlobeNewswire
Oct-17-18 09:25AM  New Research: Key Drivers of Growth for Cenovus Energy, Protalix BioTherapeutics, Rayonier Advanced Materials, B2Gold, Match Group, and Qudian Inc. Sponsored ADR Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire
Oct-05-18 08:35AM  The Daily Biotech Pulse: MediciNova Gets Orphan-Drug Status, KemPharm To Offer Shares, Emergent Buys Vaccine Maker Benzinga
07:00AM  Protalix BioTherapeutics Presents Positive Preliminary Data from the BRIDGE Study of pegunigalsidase alfa for the Treatment of Fabry Disease at the 1st Canadian Symposium on Lysosomal Diseases 2018 GlobeNewswire
Sep-30-18 10:14AM  The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Results And IPOs Benzinga
Sep-24-18 08:00AM  Todays Research Reports on Stocks to Watch: GTx and Protalix BioTherapeutics ACCESSWIRE
Sep-21-18 10:57AM  Protalix BioTherapeutics Reports Positive Preliminary Data from the BRIDGE Study of pegunigalsidase alfa for the Treatment of Fabry Disease GlobeNewswire +20.83%
Sep-17-18 07:00AM  Protalix BioTherapeutics to Present Preliminary Data from the BRIDGE Study of pegunigalsidase alfa for the Treatment of Fabry Disease at the 1st Canadian Symposium on Lysosomal Diseases 2018 GlobeNewswire
Aug-23-18 07:00AM  Protalix BioTherapeutics to Present at the 20th Annual Rodman & Renshaw Global Investment Conference GlobeNewswire
Aug-22-18 07:45AM  Research Report Identifies Nomad Foods, AutoNation, Entercom Communications, IMAX, Protalix BioTherapeutics, and Yamana Gold with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
Aug-13-18 07:00AM  Protalix BioTherapeutics Appoints David Granot to its Board of Directors GlobeNewswire
Aug-09-18 08:20AM  Protalix (PLX) Reports Q2 Loss, Misses Revenue Estimates Zacks
07:56AM  Who Owns Protalix BioTherapeutics Inc (NYSEMKT:PLX)? Simply Wall St.
07:18AM  Protalix: 2Q Earnings Snapshot Associated Press
07:00AM  Protalix BioTherapeutics Reports 2018 Second Quarter Results and Provides Corporate Update GlobeNewswire
06:30AM  Protalix Biotherapeutics, Inc. to Host Earnings Call ACCESSWIRE
Jul-31-18 07:00AM  Protalix BioTherapeutics to Hold Second Quarter 2018 Financial Results and Corporate Update Conference Call on August 9, 2018 GlobeNewswire
07:00AM  Free Technical Reports on Sarepta Therapeutics and Three Additional Biotech Equities ACCESSWIRE
Jul-24-18 09:15AM  Benzinga Pro's 5 Stocks To Watch Today Benzinga +11.62%
07:00AM  Protalix BioTherapeutics Expands Partnership with Chiesi Farmaceutici to Include Exclusive U.S. Rights for the Development and Commercialization of PRX-102 (pegunigalsidase alfa) for the Treatment of Fabry Disease GlobeNewswire
Jun-28-18 07:35AM  Complimentary Technical Snapshots on Puma Biotech and Three More Biotech Stocks ACCESSWIRE
Jun-13-18 08:00AM  Report: Exploring Fundamental Drivers Behind Virtu Financial, Littelfuse, Gogo, Brookfield Asset Management, Protalix BioTherapeutics, and Halozyme Therapeutics New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Jun-05-18 07:00AM  Protalix BioTherapeutics Announces Additional Positive Results from Final Analysis of the Phase II Clinical Trial of OPRX-106 for the Treatment of Ulcerative Colitis GlobeNewswire
May-30-18 07:00AM  Wired News - Protalix BioTherapeutics Presents Data About Fabry Disease Patients Screened in Phase-III BALANCE Study ACCESSWIRE
May-25-18 07:00AM  Protalix BioTherapeutics Announces Poster Presentation on Baseline Characteristics for Fabry Disease Patients Screened in the Phase III BALANCE Study of Pegunigalsidase Alfa at the 55th ERA-EDTA Congress GlobeNewswire
May-24-18 07:00AM  Protalix Announces Exchange and Discharge of Remaining 2018 Notes GlobeNewswire
May-10-18 07:47AM  Edited Transcript of PLX earnings conference call or presentation 9-May-18 12:30pm GMT Thomson Reuters StreetEvents
May-09-18 08:36AM  Protalix: 1Q Earnings Snapshot Associated Press
07:00AM  Protalix BioTherapeutics Reports 2018 First Quarter Results and Provides Corporate Update GlobeNewswire
Apr-26-18 07:00AM  Protalix BioTherapeutics to Hold First Quarter 2018 Financial Results and Corporate Update Conference Call on May 9, 2018 GlobeNewswire
Mar-28-18 08:15AM  Research Report Identifies Comtech Telecommunications, Protalix BioTherapeutics, Kraton, ABB, Cheniere Energy Partners LP, and Heidrick & Struggles International with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
Mar-20-18 08:05AM  Protalix BioTherapeutics, OPRX-106 Phase II Results, Analysts Review and Target, Catalysts ACCESSWIRE
Mar-19-18 07:00AM  Protalix BioTherapeutics Announces Acceptance of Abstract on OPRX-106 as a Lecture Presentation at the Digestive Diseases Week® 2018 GlobeNewswire
Mar-15-18 07:00AM  Protalix BioTherapeutics to Present at BioCenturys 25th Annual Future Leaders in the Biotech Industry Conference GlobeNewswire
Mar-13-18 08:12AM  Benzinga Pro's 5 Stock To Watch Today Benzinga
07:00AM  Protalix BioTherapeutics Announces Positive Results from Phase II Clinical Trial of OPRX-106 for the Treatment of Ulcerative Colitis GlobeNewswire
Mar-07-18 07:17AM  Edited Transcript of PLX earnings conference call or presentation 6-Mar-18 1:30pm GMT Thomson Reuters StreetEvents
Mar-06-18 07:30AM  Protalix BioTherapeutics Reports 2017 Full Year Results and Provides Corporate Update GlobeNewswire
07:23AM  Protalix BioTherapeutics Inc (NYSEMKT:PLX): Are Analysts Optimistic? Simply Wall St.
06:30AM  Protalix Biotherapeutics, Inc. to Host Earnings Call ACCESSWIRE
Feb-26-18 07:00AM  Protalix BioTherapeutics to Hold Full-Year 2017 Financial Results and Corporate Update Conference Call on March 6, 2018 GlobeNewswire
Feb-15-18 07:00AM  Protalix BioTherapeutics Announces Final Dosing of Last Patient in Phase II Clinical Trial of OPRX-106 in Patients with Ulcerative Colitis GlobeNewswire
Jan-31-18 07:30AM  Protalix BioTherapeutics pegunigalsidase alfa Receives Fast Track Designation from the U.S. Food and Drug Administration GlobeNewswire
Jan-29-18 07:00AM  Protalix BioTherapeutics to Participate in the 14th Annual WORLDSymposium 2018 GlobeNewswire
Jan-02-18 08:30AM  Company Update (NYSE:PLX): Protalix Biotherapeutics Inc Shares Fly 10% Following Impressive Phase II Interim Data in Ulcerative Colitis SmarterAnalyst
07:00AM  Protalix BioTherapeutics Reports Positive Interim Data from Phase II Clinical Trial of OPRX-106 in Patients with Ulcerative Colitis GlobeNewswire
Dec-29-17 07:00AM  Wired News - Protalix BioTherapeutics Granted Orphan Drug Designation for the Treatment of Fabry Disease ACCESSWIRE
Dec-28-17 09:11AM  Protalix (PLX) Fabry Disease Candidate Gets Orphan Status Zacks
Dec-27-17 08:50AM  Company Update (NYSE:PLX): Protalix Biotherapeutics Inc Shares Vault Another 7% After PRX-102 Wins Orphan Drug Designation from European Commission SmarterAnalyst
07:30AM  Protalix BioTherapeutics PRX-102 Granted Orphan Drug Designation by the European Commission GlobeNewswire
Nov-29-17 08:26AM  Protalix Biotherapeutics, Inc. :PLX-US: Earnings Analysis: Q3, 2017 By the Numbers : November 29, 2017 Capital Cube
07:55AM  Protalix BioTherapeutics Completes Enrollment in Phase II Clinical Trial of OPRX-106 in Patients with Ulcerative Colitis GlobeNewswire
Nov-27-17 07:00AM  Protalix BioTherapeutics Presents Positive Results from the Phase I/II Open-Label Extension Trial for PRX-102 at the New Horizons for Fabry Disease Conference GlobeNewswire
Nov-20-17 07:00AM  Protalix BioTherapeutics Announces Presentation to be made at the New Horizons in Fabry Disease Conference GlobeNewswire +6.72%
Nov-15-17 07:10AM  Corporate News Blog - Protalix BioTherapeutics Gets Positive Opinion for Orphan Designation of PRX-102 for Treatment of Fabry Disease in EU ACCESSWIRE
Nov-13-17 07:00AM  Protalix BioTherapeutics Receives Positive Opinion for Orphan Designation for PRX-102 for the Treatment of Fabry Disease in the European Union GlobeNewswire
Nov-08-17 09:03AM  Protalix reports 3Q loss Associated Press
08:55AM  Protalix Biotherapeutics Inc (PLX) Announces 3Q:17 Results and Provides Corporate Update SmarterAnalyst
07:00AM  Protalix BioTherapeutics Reports 2017 Third Quarter Results and Provides Corporate Update GlobeNewswire
Oct-31-17 07:30AM  Protalix BioTherapeutics to Hold Third Quarter 2017 Financial Results and Corporate Update Conference Call on November 8, 2017 GlobeNewswire +10.94%
Oct-19-17 08:10AM  Today's Research Reports on Stocks to Watch: Spectrum Pharmaceuticals and Protalix BioTherapeutics ACCESSWIRE -5.90%
Oct-18-17 08:39AM  Protalix Biotherapeutics Inc (PLX) Shares Skyrocket Heres Why SmarterAnalyst +26.91%
08:32AM  Protalix BioTherapeutics (PLX) Jumps: Stock Rises 9% Zacks
06:50AM  Protalix BioTherapeutics Enters into an Exclusive Ex-US Partnership with Chiesi Farmaceutici for the Development and Commercialization of PRX-102 (pegunigalsidase alfa) for the Treatment of Fabry Disease GlobeNewswire
Sep-05-17 07:30AM  Protalix Biotherapeutics to Present at the Rodman & Renshaw 19th Annual Global Investment Conference GlobeNewswire
Aug-25-17 10:39AM  Protalix Biotherapeutics, Inc. :PLX-US: Earnings Analysis: Q2, 2017 By the Numbers : August 25, 2017 Capital Cube
Aug-10-17 10:35AM  Edited Transcript of PLX earnings conference call or presentation 9-Aug-17 12:30pm GMT Thomson Reuters StreetEvents
12:18AM  Protalix posts 2Q profit Associated Press
Aug-09-17 07:00AM  Protalix BioTherapeutics Reports 2017 Second Quarter Results and Provides Corporate Update GlobeNewswire
05:50AM  Investor Network: Protalix BioTherapeutics, Inc. to Host Earnings Call ACCESSWIRE
Aug-01-17 09:40AM  LD Micro Index Reconstitution as of August 1, 2017 ACCESSWIRE
Jul-31-17 07:30AM  Protalix BioTherapeutics to Hold Second Quarter 2017 Financial Results and Corporate Update Conference Call on August 9, 2017 GlobeNewswire
Jul-25-17 04:28PM  Protalix BioTherapeutics Completes Private Note Exchange of $9 million Notes Maturing September 2018 for $8.55 million Notes Maturing February 2022 GlobeNewswire
Jun-07-17 07:30AM  Protalix BioTherapeutics Announces Phase II Clinical Trial Results for alidornase alfa in Cystic Fibrosis Presented at the 40th European Cystic Fibrosis Society Conference GlobeNewswire -5.79%
Jun-01-17 07:30AM  Protalix BioTherapeutics Announces FDA Approval to Operate its Current Facility as a Multi-Product Facility GlobeNewswire
May-30-17 08:50AM  Are Options Traders Betting on a Big Move in Protalix BioTherapeutics (PLX) Stock? Zacks
May-25-17 07:30AM  Protalix BioTherapeutics to Present at the Jefferies 2017 Global Healthcare Conference GlobeNewswire
May-23-17 07:30AM  Protalix BioTherapeutics Announces Presentation of Phase II Clinical Trial Results for alidornase alfa in Cystic Fibrosis at the 40th European Cystic Fibrosis Society Conference GlobeNewswire +10.71%
May-12-17 11:37AM  Protalix Biotherapeutics, Inc. :PLX-US: Earnings Analysis: Q1, 2017 By the Numbers : May 12, 2017 Capital Cube
May-11-17 07:30AM  Edited Transcript of PLX earnings conference call or presentation 10-May-17 12:30pm GMT Thomson Reuters StreetEvents
May-10-17 07:40AM  Protalix reports 1Q loss Associated Press
07:30AM  Protalix BioTherapeutics Reports 2017 First Quarter Results and Provides Corporate Update GlobeNewswire
May-09-17 07:30AM  Protalix Announces FDA Investigational New Drug Clearance to Commence Once-Monthly Dosing Study of pegunigalsidase alfa (PRX-102) for the Treatment of Fabry Disease GlobeNewswire
May-01-17 07:50AM  Protalix BioTherapeutics to Hold First Quarter 2017 Financial Results and Corporate Update Conference Call on May 10, 2017 GlobeNewswire
Apr-18-17 07:30AM  Protalix BioTherapeutics Announces New Preclinical Results Demonstrating a Positive Effect of pegunigalsidase alfa (PRX-102) on Small-fiber Neuropathy in Fabry Disease Models Compared to Commercially Available Enzyme Replacement Therapies GlobeNewswire
Apr-13-17 07:30AM  Apricus Biosciences and Protalix Biotherapeutics Seeing Opposite Sides of FDA Clinical Trials Accesswire -5.41%
Apr-12-17 09:20AM  Protalix Cystic Fibrosis Drug Study Results Worsen Over Time TheStreet.com -15.27%
Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in Israel and internationally. The company offers Elelyso, a plant cell expressed recombinant glucocerebrosidase enzyme for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in phase III clinical trials to treat Fabry diseases; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that is in phase IIa clinical trials for the treatment of cystic fibrosis; and OPRX-106, an oral anti TNF product candidate, which is in Phase IIa clinical trial for the treatment of ulcerative colitis. Protalix BioTherapeutics, Inc. was founded in 1993 and is based in Karmiel, Israel.